HEMO vs. FARN, ARIX, CIR, BVXP, 4BB, TILS, VSN, SCLP, MPH, and ORPH
Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals vs. Its Competitors
Hemogenyx Pharmaceuticals (LON:HEMO) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
In the previous week, Hemogenyx Pharmaceuticals had 2 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 4 mentions for Hemogenyx Pharmaceuticals and 2 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.97 beat Hemogenyx Pharmaceuticals' score of 0.84 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.
Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Hemogenyx Pharmaceuticals has a beta of 3.14, meaning that its stock price is 214% more volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.
1.3% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Faron Pharmaceuticals Oy's return on equity of 0.46% beat Hemogenyx Pharmaceuticals' return on equity.
Summary
Hemogenyx Pharmaceuticals beats Faron Pharmaceuticals Oy on 6 of the 10 factors compared between the two stocks.
Get Hemogenyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hemogenyx Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HEMO) was last updated on 10/6/2025 by MarketBeat.com Staff
